129
Views
22
CrossRef citations to date
0
Altmetric
Conference papers

A role for surface reactivity in TiO2 and quartz-related nanoparticle pulmonary toxicity

, , , , &
Pages 181-187 | Received 20 Oct 2008, Published online: 09 Sep 2009

References

  • Clouter A, Brown D, Hohr D, Borm P, Donaldson K. Inflammatory effects of respirable quartz collected in workplaces versus standard DQ12 quartz: particle surface correlates. Toxicol Sci 2001; 63: 90–98
  • Donaldson K, Stone V, Clouter A, Renwick L, MacNee W. Ultrafine particles. Occup Environ Med 2001; 58: 211–216
  • Harington JS, Macnab GM, Miller K, King PC. Enhancement of haemolytic activity of asbestos by heat-labile factors in fresh serum. Med Lav 1971; 62: 171–176
  • Nano Risk Framework. 2007, Accessed from the internet website:, www.nanoriskframework.com.
  • Nolan RP, Langer AM, Harington JS, Oster G, Selikoff IJ. Quartz hemolysis as related to its surface functionalities. Environ Res 1981; 26: 503–520
  • Oberdörster G. Toxicology of ultrafine particles: In vivo studies. Phil Trans R Soc London A 2000; 358: 2719–2740
  • Rajh T, Nedeljkovic M, Chen LX, Poluektov O, Thurnauer MC. Improving optical and charge separation properties of nanocrystalline TiO2 by surface modification with vitamin C. J Phys Chem B 1999; 103: 3515
  • Razzaboni BL, Bolsaitis P. Evidence of an oxidative mechanism for the hemolytic activity of silica particles. Environ Health Perspect 1990; 87: 337–341
  • Warheit DB, Webb TR, Reed KL, Frerichs S, Sayes CM. Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: Differential responses related to surface properties. Toxicology 2007a; 230: 90–104
  • Warheit DB, Webb TR, Colvin VL, Reed KL, Sayes CM. Pulmonary bioassay studies with nanoscale and fine quartz particles in rats: Toxicity is not dependent upon particle size but on surface characteristics. Toxicol Sci 2007b; 95: 270–280
  • Warheit DB, Sayes CM, Reed KL, Swain KA. Health effects related to nanoparticle exposures: Environmental, health and safety considerations for assessing hazards and risks. Pharmacol Therapeut 2008; 120: 35–42

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.